PaulJ.ShaughnessyMD

Oncology • San Antonio, TX

Hematologic Oncology

Assistant Professor of Medicine, University Tex San Antonio

Join to view full profile

Are you Dr. Shaughnessy?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 87 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
7700 Floyd Curl Dr
10TH floor
San Antonio, TX 78229
Phone+1 210-575-3817

Fax+1 210-575-4113

Summary

Dr. Paul Shaughnessy, MD is an oncologist in San Antonio, Texas. He is currently licensed to practice medicine in Texas and Pennsylvania. He is affiliated with Methodist Hospital and is an Assistant Professor of Medicine at University Tex San Antonio.

Education & Training

San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1994 - 1997
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1991 - 1994
Indiana University School of MedicineClass of 1991

Certifications & Licensure

TX State Medical License 1998 - 2026
PA State Medical License 1993 - 1998
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Top Doctors:SE Texas Castle Connolly, 2013

Clinical Trials

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Start of enrollment: 2003 Nov 01
Completed
Phase 3
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies Start of enrollment: 2006 Jul 01
Completed
Phase 2
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Completed
Not Applicable
Allogeneic Transplant in HIV Patients (BMT CTN 0903) Start of enrollment: 2011 Sep 01
Completed
Phase 2
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies Start of enrollment: 2013 Aug 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

427 citations
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.
Paul J. Martin, J. Douglas Rizzo, John R. Wingard, Karen K. Ballen, Peter T. Curtin
Biology of Blood and Marrow Transplantation. 2012-08-01
282 citations
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
Sergio Giralt, Luciano J. Costa, Jeffrey Schriber, John F. DiPersio, Richard T. Maziarz
Biology of Blood and Marrow Transplantation. 2014-03-01
79 citations
Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
Paul J. Shaughnessy, Miguel Islas-Ohlmayer, Julie Murphy, Maureen Hougham, Jill MacPherson
Biology of Blood and Marrow Transplantation. 2011-05-01

Press Mentions

Sarah Cannon Blood Cancer Network Leaders to Present 24 Abstracts at the 2016 BMT Tandem MeetingsFebruary 16th, 2016